ScinoPharm, Foresee partner to deliver cancer drug

Taiwanese drugmaker ScinoPharm will use Foresee Pharmaceuticals' controlled-release technology to produce a generic prostate cancer drug. ScinoPharm contributed a $3.6 million minority stake to the joint venture, aiming to combine Foresee's delivery technology with the drug leuprolide acetate, a peptide injectable scheduled for a Phase III trial late this year. It is ScinoPharm's first foray into new drug development, and the company said it is the first in a series that solidifies its decision last year to invest in cancer drugs and injectables in the wake of global shortages. Release | Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…